01-014 · EVIDENCE A · SOURCE-SENSITIVE
Get tested for hepatitis B markers; if no antibodies, get vaccinated
查乙肝两对半,没有抗体就打疫苗
The test costs just a few dozen yuan per person. For adults lacking antibodies, three doses of the hepatitis B vaccine cost between 100 and 300 yuan total, to be completed within six months.
The test itself is very inexpensive. In Qidong’s 30‑year follow‑up study, infants who received the hepatitis B vaccine at birth had an 84% lower risk of developing primary liver cancer and a 72% lower rate of carrying the hepatitis B virus compared to unvaccinated peers. Adults found to have no antibodies should receive three vaccine doses over six months at a cost of roughly 100–300 yuan.
A
Move “Get tested for hepatitis B markers; if no antibodies, get vaccinated” to Future Me's calendar
The excuse
There is no immediate alarm, so the sensible choice can wait for a less busy week.
What feels good now
Today I keep a little money, a few minutes and avoid interrupting my default routine.
What the source says
The source summarizes the return this way: “The test itself is very inexpensive. In Qidong’s 30‑year follow‑up study, infants who received the hepatitis B vaccine at birth had an 84% lower risk of developing primary liver cancer and a 72% lower rate of carrying the hepatitis B virus compared to unvaccinated peers. Adults found to have no antibodies should receive three vaccine doses over six months at a cost of roughly 100–300 yuan.” Evidence grade A. The original states the population, caveats, and sources; this is not a personal forecast.
Use the original facts and limits. For an urgent medical, safety, financial, or legal issue, contact a qualified local professional or service.
THE ENGLISH EDITION
Original recommendation and evidence
14. Get tested for hepatitis B markers; if no antibodies, get vaccinated
Cost: The test costs just a few dozen yuan per person. For adults lacking antibodies, three doses of the hepatitis B vaccine cost between 100 and 300 yuan total, to be completed within six months.
In plain terms: The test itself is very inexpensive. In Qidong’s 30‑year follow‑up study, infants who received the hepatitis B vaccine at birth had an 84% lower risk of developing primary liver cancer and a 72% lower rate of carrying the hepatitis B virus compared to unvaccinated peers. Adults found to have no antibodies should receive three vaccine doses over six months at a cost of roughly 100–300 yuan.
Benefit: This Qidong trial used group randomization rather than individual assignment and was tracked for three decades. Vaccination at birth cut primary liver cancer incidence by 84% (95% CI 23%–97%). The prevalence of hepatitis B surface antigen (HBsAg) fell by 72% (95% CI 68%–75%), reflecting a comparable drop in the proportion of people carrying the virus. Nationwide in China, HBsAg prevalence dropped 52% between 1992 and 2014, and fell 97% among children under five.
Evidence grade: A
Sources: Qu C et al. (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study. PLoS Medicine. <https://doi.org/10.1371/journal.pmed.1001774>; Cui F et al. (2017). Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases. <https://doi.org/10.3201/eid2305.161477>
Notes: This recommendation applies to adults born before 1992 who never received the vaccine or whose antibodies have waned. The 84% cancer‑risk reduction pertains only to those immunized at birth; adolescents vaccinated later saw only a 21% reduction in virus carriage. For adults, the main goal is preventing new infection, not achieving the same cancer‑prevention benefit. Vaccination offers no protection to people already infected; they must see a hepatologist regularly. Infection is confirmed when the hepatitis B surface antigen (HBsAg) test result is positive.
Source links
- Qu C 等 (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study. PLoS Medicine. ↗
- Cui F 等 (2017). Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases. ↗
- Pinned original chapter on GitHub ↗
Read the complete Chinese source and notes
14. 查乙肝两对半,没有抗体就打疫苗
成本: 查一次几十元。成人乙肝疫苗 3 针合起来 100 到 300 元。半年之内打完。
说人话: 查一次几十块。启东那项跟踪了 30 年的试验里,一出生就打了乙肝疫苗的人,后来得原发性肝癌的概率低 84%,身上带着乙肝病毒的比例低 72%。成人查出没抗体的补三针,半年打完,一两百块。
收益: 启东那项试验按群体随机分组,不是按个人分组,跟踪了 30 年。新生儿接种乙肝疫苗,原发性肝癌下降 84%。可信范围是 95% CI 23% 到 97%。乙肝表面抗原 HBsAg 阳性率下降 72%(95% CI 68% 到 75%),这个阳性率就是查出身上带着病毒的人所占的比例。中国全人群的 HBsAg 阳性比例,1992 到 2014 年下降 52%,5 岁以下下降 97%
证据等级: A
来源: Qu C 等 (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study. PLoS Medicine. <https://doi.org/10.1371/journal.pmed.1001774> ; Cui F 等 (2017). Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerging Infectious Diseases. <https://doi.org/10.3201/eid2305.161477>
备注: 这条适用于 1992 年前出生、没打过疫苗或者抗体已经消失的成人。肝癌下降 84% 那个数来自一出生就打的人。同一项试验里,到青少年才补打的,防住病毒携带的效力只有 21%。成人打主要图的是不再被感染,不能直接套那个 84%。已经感染的人打疫苗没用,要去肝病科定期复查。怎么算已经感染:化验单上乙肝表面抗原 HBsAg 那一项是阳性。
YOUR PRIVATE LIST